199 related articles for article (PubMed ID: 29109117)
1. Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia.
Delker DA; Wood AC; Snow AK; Samadder NJ; Samowitz WS; Affolter KE; Boucher KM; Pappas LM; Stijleman IJ; Kanth P; Byrne KR; Burt RW; Bernard PS; Neklason DW
Cancer Prev Res (Phila); 2018 Jan; 11(1):4-15. PubMed ID: 29109117
[TBL] [Abstract][Full Text] [Related]
2. Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial.
Samadder NJ; Neklason DW; Boucher KM; Byrne KR; Kanth P; Samowitz W; Jones D; Tavtigian SV; Done MW; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Davis R; Topham MK; Lynch P; Strait E; McKinnon W; Burt RW; Kuwada SK
JAMA; 2016 Mar 22-29; 315(12):1266-75. PubMed ID: 27002448
[TBL] [Abstract][Full Text] [Related]
3. Molecular Predicators of Duodenal Familial Adenomatous Polyposis Chemoprevention: Do Chemopreventive Drugs Hit Their Presumed Molecular Targets?
Shureiqi I
Cancer Prev Res (Phila); 2018 Jan; 11(1):1-3. PubMed ID: 29263155
[TBL] [Abstract][Full Text] [Related]
4. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
Samadder NJ; Kuwada SK; Boucher KM; Byrne K; Kanth P; Samowitz W; Jones D; Tavtigian SV; Westover M; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Burt RW; Neklason DW
JAMA Oncol; 2018 May; 4(5):671-677. PubMed ID: 29423501
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis.
Samadder NJ; Foster N; McMurray RP; Burke CA; Stoffel E; Kanth P; Das R; Cruz-Correa M; Vilar E; Mankaney G; Buttar N; Thirumurthi S; Turgeon DK; Sossenheimer M; Westover M; Richmond E; Umar A; Della'Zanna G; Rodriguez LM; Szabo E; Zahrieh D; Limburg PJ
Gut; 2023 Feb; 72(2):256-263. PubMed ID: 35636921
[TBL] [Abstract][Full Text] [Related]
7. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
Bowen CM; Walter L; Borras E; Wu W; Ozcan Z; Chang K; Bommi PV; Taggart MW; Thirumurthi S; Lynch PM; Reyes-Uribe L; Scheet PA; Sinha KM; Vilar E
Cancer Prev Res (Phila); 2021 Sep; 14(9):851-862. PubMed ID: 34266857
[TBL] [Abstract][Full Text] [Related]
8. Gene Expression Changes Accompanying the Duodenal Adenoma-Carcinoma Sequence in Familial Adenomatous Polyposis.
Thiruvengadam SS; OʼMalley M; LaGuardia L; Lopez R; Wang Z; Shadrach BL; Chen Y; Li C; Veigl ML; Barnholtz-Sloan JS; Pai RK; Church JM; Kalady MF; Walsh RM; Burke CA
Clin Transl Gastroenterol; 2019 Jun; 10(6):e00053. PubMed ID: 31211760
[TBL] [Abstract][Full Text] [Related]
9. Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism.
Brosens LA; Iacobuzio-Donahue CA; Keller JJ; Hustinx SR; Carvalho R; Morsink FH; Hylind LM; Offerhaus GJ; Giardiello FM; Goggins M
Clin Cancer Res; 2005 Jun; 11(11):4090-6. PubMed ID: 15930344
[TBL] [Abstract][Full Text] [Related]
10. Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP).
Ulusan AM; Rajendran P; Dashwood WM; Yavuz OF; Kapoor S; Gustafson TA; Savage MI; Brown PH; Sei S; Mohammed A; Vilar E; Dashwood RH
Cancer Prev Res (Phila); 2021 Mar; 14(3):325-336. PubMed ID: 33277315
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.
Gross ND; Bauman JE; Gooding WE; Denq W; Thomas SM; Wang L; Chiosea S; Hood BL; Flint MS; Sun M; Conrads TP; Ferris RL; Johnson JT; Kim S; Argiris A; Wirth L; Nikiforova MN; Siegfried JM; Grandis JR
Clin Cancer Res; 2014 Jun; 20(12):3289-98. PubMed ID: 24727329
[TBL] [Abstract][Full Text] [Related]
12. Variables affecting penetrance of gastric and duodenal phenotype in familial adenomatous polyposis patients.
Sample DC; Samadder NJ; Pappas LM; Boucher KM; Samowitz WS; Berry T; Westover M; Nathan D; Kanth P; Byrne KR; Burt RW; Neklason DW
BMC Gastroenterol; 2018 Jul; 18(1):115. PubMed ID: 30012100
[TBL] [Abstract][Full Text] [Related]
13. Sulindac plus erlotinib for familial adenomatous polyposis.
Baker H
Lancet Oncol; 2016 May; 17(5):e183. PubMed ID: 27051970
[No Abstract] [Full Text] [Related]
14. Burden and Profile of Somatic Mutation in Duodenal Adenomas from Patients with Familial Adenomatous- and
Thomas LE; Hurley JJ; Meuser E; Jose S; Ashelford KE; Mort M; Idziaszczyk S; Maynard J; Brito HL; Harry M; Walters A; Raja M; Walton SJ; Dolwani S; Williams GT; Morgan M; Moorghen M; Clark SK; Sampson JR
Clin Cancer Res; 2017 Nov; 23(21):6721-6732. PubMed ID: 28790112
[No Abstract] [Full Text] [Related]
15. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis.
Nugent KP; Farmer KC; Spigelman AD; Williams CB; Phillips RK
Br J Surg; 1993 Dec; 80(12):1618-9. PubMed ID: 8298943
[TBL] [Abstract][Full Text] [Related]
16. Epithelial turnover in duodenal familial adenomatous polyposis: A possible role for estrogen receptors?
Di Leo A; Nesi G; Principi M; Piscitelli D; Girardi B; Pricci M; Losurdo G; Iannone A; Ierardi E; Tonelli F
World J Gastroenterol; 2016 Mar; 22(11):3202-11. PubMed ID: 27003997
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention in familial adenomatous polyposis: past, present and future.
Kemp Bohan PM; Mankaney G; Vreeland TJ; Chick RC; Hale DF; Cindass JL; Hickerson AT; Ensley DC; Sohn V; Clifton GT; Peoples GE; Burke CA
Fam Cancer; 2021 Jan; 20(1):23-33. PubMed ID: 32507936
[TBL] [Abstract][Full Text] [Related]
18. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months.
Winde G; Schmid KW; Schlegel W; Fischer R; Osswald H; Bünte H
Dis Colon Rectum; 1995 Aug; 38(8):813-30. PubMed ID: 7634976
[TBL] [Abstract][Full Text] [Related]
19. The impact of chromoendoscopy for surveillance of the duodenum in patients with MUTYH-associated polyposis and familial adenomatous polyposis.
Hurley JJ; Thomas LE; Walton SJ; Thomas-Gibson S; Haycock A; Suzuki N; Mort M; Williams G; Morgan M; Clark SK; Sampson JR; Dolwani S
Gastrointest Endosc; 2018 Oct; 88(4):665-673. PubMed ID: 29702101
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.
van Heumen BW; Roelofs HM; Vink-Börger ME; Dekker E; Mathus-Vliegen EM; Dees J; Koornstra JJ; Langers AM; Nagtegaal ID; Kampman E; Peters WH; Nagengast FM
Orphanet J Rare Dis; 2013 Aug; 8():118. PubMed ID: 23919274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
